Shared Decision Making in Low Risk Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01673581 |
Recruitment Status
:
Active, not recruiting
First Posted
: August 28, 2012
Last Update Posted
: August 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Prostate Cancer | Other: Survey |
Investigators will first ask patients to answer a series of questions to assess their wishes regarding treatment, knowledge about their disease and discussion with the physicians at initial patient visit. This initial survey should take approximately 20 minutes. Once patients have selected a treatment path investigators will contact them again and ask them to fill out a short 10-minute survey online or by mail. Investigators will contact patients by phone 2 weeks after their initial visit to see if they have made a decision. If not, investigators will contact patients by phone every 2 weeks or at an interval that works for the patient's schedule. Finally, 3 months after the initial visit today investigators will contact patients for the last time and again ask you to fill out a short 10-minute survey online or by mail.
Once patients have completed the final survey there are no future surveys planned. Investigators may contact patients by phone in the future to ask them to participate in another study.
Study Type : | Observational |
Actual Enrollment : | 141 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Shared Decision Making: A Study Assessing the Benefit of a Web Based Aid Presenting Treatment Options for Patients With Low Risk Prostate Cancer |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | December 2015 |

Group/Cohort | Intervention/treatment |
---|---|
Low risk prostate cancer | Other: Survey |
- Patient knowledge regarding the available treatment options for low-risk prostate cancer and their potential side effects. [ Time Frame: 2 years ]Investigators will assess the impact of an informational website developed specifically to assist low-risk prostate cancer patients with knowledge of their disease and treatment options. This will be measured by patient responses to questionnaires compiled from validated sources.
- Decisional conflict and informed decision making experienced by patients. [ Time Frame: 2 years ]Investigators will assess the impact of an informational website developed specifically to assist low-risk prostate cancer patients with knowledge of their disease and treatment options. This will be measured by patient responses to questionnaires compiled from validated sources.
- Patient health related worry. [ Time Frame: 2 years ]Investigators will assess the impact of an informational website developed specifically to assist low-risk prostate cancer patients with knowledge of their disease and treatment options. This will be measured by patient responses to questionnaires compiled from validated sources.
- Patient views on cancer control for their treatment choice. [ Time Frame: 2 years ]Investigators will assess the impact of an informational website developed specifically to assist low-risk prostate cancer patients with knowledge of their disease and treatment options. This will be measured by patient responses to questionnaires compiled from validated sources.
- Patient satisfaction with their treatment choice. [ Time Frame: 2 years ]Investigators will assess the impact of an informational website developed specifically to assist low-risk prostate cancer patients with knowledge of their disease and treatment options. This will be measured by patient responses to questionnaires compiled from validated sources.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma
- Internet access
- Able to read and understand English
Exclusion Criteria:
- Evidence of nodal metastases
- Evidence of distant metastases
- Prior surgery, chemotherapy, pelvic radiation or prostate brachytherapy for prostate cancer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01673581
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Jason A. Efstathiou, MD, DPhil | Massachusetts General Hospital |
Responsible Party: | Jason Efstathiou, Principal Investigator, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT01673581 History of Changes |
Other Study ID Numbers: |
11-463 |
First Posted: | August 28, 2012 Key Record Dates |
Last Update Posted: | August 29, 2017 |
Last Verified: | August 2017 |
Keywords provided by Jason Efstathiou, Massachusetts General Hospital:
Low Risk |
Additional relevant MeSH terms:
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |